Free Trial
NASDAQ:ZVSA

ZyVersa Therapeutics Q2 2023 Earnings Report

ZyVersa Therapeutics logo
$0.68 +0.13 (+24.24%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$0.61 -0.07 (-10.34%)
As of 08:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZyVersa Therapeutics EPS Results

Actual EPS
-$1,459.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ZyVersa Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ZyVersa Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 21, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

ZyVersa Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ZyVersa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ZyVersa Therapeutics and other key companies, straight to your email.

About ZyVersa Therapeutics

ZyVersa Therapeutics (NASDAQ:ZVSA), a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

View ZyVersa Therapeutics Profile

More Earnings Resources from MarketBeat